Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.15107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Jun Sugisaka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
There is no well‐established late‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Therefore, we retrospectively determined the efficacy and safety of platinum rechallenge with paclitaxel‐carboplatin and bevacizumab in patients with nonsquamous NSCLC as a late‐line therapy in a clinical setting.
Methods
Thirty patients with nonsquamous NSCLC who received paclitaxel‐carboplatin with bevacizumab therapy as a late‐line treatment at Sendai Kousei Hospital (Miyagi, Japan) between December 2011 and December 2021 were enrolled into the study. The efficacy and safety of this treatment were evaluated. The patients were further categorized into responders and nonresponders, and predictive factors of treatment response were estimated.
Results
The median progression‐free survival (PFS) was 6.3 (range, 4.9–6.8) months, and the median overall survival (OS) was 11.8 (range, 7.2–17.2) months. There were no significant differences in PFS and OS between patients with and those without epidermal growth factor receptor mutations. In the univariate analyses of this study, responders were younger than nonresponders ( p = 0.012). No fatal adverse events were reported.
Conclusions
With the increase in the number of treatment options in recent years, the sequence of treatments and overall therapeutic strategy are becoming increasingly important. Thus, platinum rechallenge with paclitaxel‐carboplatin and bevacizumab, a late‐line treatment for patients with nonsquamous NSCLC, may be an effective therapeutic option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
ORCID-Profile: Jun Sugisaka, Yosuke Kawashima, Shunichi Sugawara
Zitieren
APA
Sugisaka, J., Toi, Y., Kawashima, Y., Domeki, Y., Aiba, T., Kawana, S., Nakamura, A., Yamanda, S., Kimura, Y., & Sugawara, S. (2023). Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15107
Vancouver
Sugisaka J, Toi Y, Kawashima Y, Domeki Y, Aiba T, Kawana S, et al. Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15107
BibTeX
@article{Sugisaka2023,
author = {Sugisaka, Jun and Toi, Yukihiro and Kawashima, Yosuke and Domeki, Yutaka and Aiba, Tomoiki and Kawana, Sachiko and Nakamura, Atsushi and Yamanda, Shinsuke and Kimura, Yuichiro and Sugawara, Shunichi},
title = {Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.15107}
}
EUVIMED